aod 9604 with tirzepatide Understanding 9604: The Science of the “Fat-Burning” Peptide Fragment aod9604 and tirzepatide Exploring the

The clinical insights from these studies demonstrate how our portfolio may offer more tailored, individualised treatment options for people living with obesity. The data presented on Roches obesity assets include: Enicepatide (CT-388) : Late-breaking data from the Phase II (CT388-103) study will highlight clinical weight loss outcomes from investigational enicepatide in people living with overweight/obesity

Thats where weight loss injections come into play

13%, p = 0.032) 20

This is a clean, easy-to-measure setup

While highly praised for ease of use, it generates significant plastic waste and lacks dose flexibility